Key statistics dashboard for Citius Pharmaceuticals, Inc. (CTXR). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies.
Stock Data
| Price | $0.56 |
| Market Cap | $6M |
| Beta | 1.38 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.27 |
| Price / Book | 0.22 |
| P/S | 0.88 |
| P/FCF | -0.18 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 19.97% |
| EBIT Margin | -863.17% |
| EBITDA Margin | -804.65% |
| Operating Margin | -863.92% |
| Net Margin | -651.27% |
Financial Health
| Current Ratio | 0.84 |
| Quick Ratio | 0.40 |
| Cash Ratio | 0.33 |
| Debt / Equity | 0.11 |
| Debt / Assets | 5.05% |
| Interest Coverage | -88.28 |
Per-Share Data
| Revenue per share | 0.27 |
| Book Value per share | 2.90 |
| Cash per share | 0.65 |
| FCF per share | -1.33 |
| Tangible Book Value per share | -0.85 |
| Dividend per share | 0.00 |
Related companies: ADTX · APLM · ATHA · CRIS · DARE · FBLG · ICU
Explore sector: Healthcare · Biotechnology
More sections of CTXR: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks